AURANOFIN - ORAL CHRYSO-THERAPEUTIC AGENT FOR TREATMENT OF RHEUMATOID-ARTHRITIS

  • 1 January 1978
    • journal article
    • research article
    • Vol. 5  (1) , 68-74
Abstract
Auranofin, an oral chrysotherapeutic agent, administered at 3.0 mg, 4 times daily orally to 8 rheumatoid arthritic patients, produced improvement in objective and subjective clinical signs, and biochemical and immunological parameters. Adverse effects reported were minimal and generally limited to gastrointestinal disturbances. During auranofin administration, Au concentrations in the blood gradually increased to a mean level of 0.70 .mu.g Au/ml by wk 12 of treatment. Daily oral administration of auranofin appears to provide constant blood Au levels over longer periods of time compared to existing parenteral Au therapy and may provide an improved method of controlling chrysotherapy in rheumatoid arthritic patients.

This publication has 1 reference indexed in Scilit: